The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas

Cancer

Volumn 82, Issue 11, 1998, Pages 2262-2269

  Perry, Arie ^a   Stafford, Scott L ^a   Scheithauer, Bernd W ^a   Suman, Vera J ^a   Lohse, Christine M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain; Flow cytometry; Ki 67; Meningioma; MID 1; p53 protein; Prognosis; Recurrence

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER RECURRENCE; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MENINGIOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NUCLEAR PROTEINS; PLOIDIES; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032102464     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R     Document Type: Article

References (56)

1. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20:22-39.
2. Skullerud K, Löken AC. The prognosis in meningiomas. Acta Neuropathol 1974;29:337-44.
3. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol 1975;208:279-98.
4. MacCarty CS, Taylor WF. Intracranial meningiomas: experiences at the Mayo Clinic. Neurologia Medico-Chirurgica 1979;19:569-74.
5. Böker D-K, Meurer H, Gullotta F. Recurring intracranial meningiomas: evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 1985;29:11-7.
6. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18-24.
7. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 1986;10:836-43.
8. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233-42.
9. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.
10. Rohringer M, Sutherland GR, Louw DF, Sima AAF. Incidence and clinicopathological features of meningioma. J Neurosurg 1989;71:665-72.
11. Chen WYK, Liu HC. Atypical (anaplastic) meningioma: relationship between histologic features and recurrence - a clinicopathologic study. Clin Neuropathol 1990;9:74-81.
12. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 1992; 31:2-12.
13. Maier H, Öfner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-23.
14. Sankila R, Kallio M, Jääskeläinen J, Hakulinen T. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland. Cancer 1992;70:1568-76.
15. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993;33:955-63.
16. McLean CA, Jolley D, Cukier E, Giles G, Gonzales MF. Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicator. Histopathology 1993;23: 349-53.
17. Hsu DW, Pardo FS, Efird JT, Linggood RM, Hedley-Whyte ET. Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 1994;53:247-55.
18. Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir 1994;126:53-8.
19. Miller DC. Predicting recurrence of intracranial meningiomas: a multivariate clinicopathologic model - interim report of the New York University Medical Center Meningioma Project. Neurosurg Clin North Am 1994;5: 193-200.
20. Yao Y-T. Clinicopathologic analysis of 615 cases of meningioma with special reference to recurrence. J Formos Med Assoc 1994;93:145-52.
21. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455-65.
22. Stafford SL, Perry A, Suman V, Meyer B, Scheithauer BW, et al. Outcome and analysis of prognostic factors of primarily resected tumors. Int J Radiat Oncol Biol Phys 1996; 36(Suppl):287.
23. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
24. Vindelov L, Christensen I, Nissen N. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
25. Gonchoroff NJ, Ryan JJ, Kimlinger TK, Witzig TE, Greipp PR, Meyer JS, et al. Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry. Cytometry 1990; 11:642-6.
26. Dressler LG, Seamer L, Owens MA, Clark GM, McGuire WL. Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res 1987;47:5294-302.
27. Ironside JW, Battersby RDE, Lawry J, Loomes RS, Day CA, Timperley WR. DNA in meningioma tissues and explant cell cultures: a flow cytometric study with clinicopathological correlates. J Neurosurg 1987;66:588-94.
28. Cruz-Sánchez FF, Miquel R, Rossi ML, Figols J, Palacin A, Cardesa A. Clinicopathological correlations in meningiomas: a DNA and immunohistochemical study. Histol Histopathol 1993;8:1-8.
29. Salmon I, Kruczynski A, Camby I, Levivier M, Pasteels J-L, Brotchi J, et al. DNA histogram typing in a series of 707 tumors of the central and peripheral nervous system. Am J Surg Pathol 1993;17:1020-8.
30. Strachan R, Clarke C, Nurbhai M, Marks S. Will chromosome karyotyping of meningiomas aid prediction of tumour recurrence? Br J Neurosurg 1989;3:583-90.
31. Vagner-Capodano AM, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas. Neurosurgery 1993;32:892-900.
32. Lekanne Deprez RH, Riegman PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54: 224-35.
33. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW. Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Cancer 1996; 77:2567-73.
34. May PL, Broome JC, Lawry J, Buxton RA, Battersby RDE. The prediction of recurrence in meningiomas: a flow cytometric study of paraffin-embedded archival material. J Neurosurg 1989;71:347-51.
35. Salmon I, Kiss R, Levivier M, Remmelink M, Pasteels J-L, Brotchi J, et al. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. Am J Surg Pathol 1993;17: 239-47.
36. Linden MD, El-Naggar AK, Nathanson SD, Jacobson G, Zarbo RJ. Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Mod Pathol 1996;9:682-9.
37. Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence. Acta Neuropathol 1990;80:311-7.
38. Shibuya M, Hoshino T, Ito S, Wacker MR, Prados MD, Davis RL, et al. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling. Neurosurgery 1992;30:494-8.
39. Shibuya M, Ito S, Miwa T, Davis RL, Wilson CB, Hoshino T. Proliferative potential of brain tumors: analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Cancer 1993;71:199-206.
40. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma: indicators for the prediction of biologic potential and postoperative management. Cancer 1994; 74:3176-89.
41. Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol (Berl) 1987;73:361-4.
42. Schröder R, Bien K, Kott R, Meyers I, Vössing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol 1991;82:389-94.
43. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
44. Nakasu S, Nakajima M, Matsumura K-I, Nakasu Y, Handa J. Meningioma: proliferating potential and clinicoradiological features. Neurosurgery 1995;37:1049-55.
45. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol 1996;27: 350-4.
46. Matsuno A, Nagashima T, Matsuura R, Tanaka H, Hirakawa M, Murakami M, et al. Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas. Am J Clin Pathol 1996;106: 776-81.
47. Prayson RA. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. Am J Clin Pathol 1996;105:719-26.
48. Radhakrishnan W, Radhakrishnan NS, Rout D, Misna BK. Nucleolar organizer regions in meningiomas. Br J Neurosurg 1993;7:377-81.
49. Kunishio K, Ohmoto T, Matsuhisa T, Maeshiro T, Furuta T, Matsumoto K. The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence. Cancer 1994;73:2200-5.
50. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991; 6:1313-8.
51. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80.
52. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA. Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 1995;82:106-15.
53. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC. Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 1995;21:136-42.
54. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, et al. Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 1995;64: 223-8.
55. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.
56. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 1993; 85:611-6.